SE9904177D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE9904177D0
SE9904177D0 SE9904177A SE9904177A SE9904177D0 SE 9904177 D0 SE9904177 D0 SE 9904177D0 SE 9904177 A SE9904177 A SE 9904177A SE 9904177 A SE9904177 A SE 9904177A SE 9904177 D0 SE9904177 D0 SE 9904177D0
Authority
SE
Sweden
Prior art keywords
lower alkyl
aryl
acyl
alkyl
alkoxy
Prior art date
Application number
SE9904177A
Other languages
Swedish (sv)
Inventor
Magnus Ingelman-Sundberg
Anastasia Simi
Niclas Tindberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9904177A priority Critical patent/SE9904177D0/en
Publication of SE9904177D0 publication Critical patent/SE9904177D0/en
Priority to PCT/SE2000/002252 priority patent/WO2001035959A1/en
Priority to AU16531/01A priority patent/AU1653101A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the use of a compound of general formula (I) or (II) wherein R1 is H, lower alkyl, lower alkoxy-lower alkyl, aryl-lower alkyl or CF3; R2 and R3 are independently H, lower alkyl, lower alkoxy-lower alkyl, aryl-lower alkyl, (a), with the proviso that one of R2 or R3 is (b) wherein W is O, S, NH or N-lower alkyl; R4 is H, lower alkyl or lower acyl; R5 is H, lower alkyl, aryl-lower alkyl, cyclopropyl or lower perfluoroalkyl; Ar is phenyl, furyl, thienyl, naphthyl, pyridyl or pyrrolyl, optionally substituted by R6; R6 is one or more groups selected from lower alkyl, lower acyl, halogen, lower alkoxy, CF3, OH, NO2 or NR7R8, wherein R7 and R8 independently are H, lower alkyl or lower acyl; R9 is CH2-halogen, CH3 or COOH; R10 is H, OH or =O; R11 is H or OH; geometrical and optical isomers, tautomers and racemates thereof where such isomers or tautomers exist, as well as pharmaceutically acceptable acid addition salts thereof and solvates thereof, for the preparation of a medicament for the treatment and/or prevention of p38 MAP kinase mediated disorders.
SE9904177A 1999-11-18 1999-11-18 Novel compounds SE9904177D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE9904177A SE9904177D0 (en) 1999-11-18 1999-11-18 Novel compounds
PCT/SE2000/002252 WO2001035959A1 (en) 1999-11-18 2000-11-15 Use of thiazole derivatives for treatment/prevention of p38 kinase mediated disorders
AU16531/01A AU1653101A (en) 1999-11-18 2000-11-15 Use of thiazole derivatives for treatment/prevention of p38 kinase mediated disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904177A SE9904177D0 (en) 1999-11-18 1999-11-18 Novel compounds

Publications (1)

Publication Number Publication Date
SE9904177D0 true SE9904177D0 (en) 1999-11-18

Family

ID=20417767

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9904177A SE9904177D0 (en) 1999-11-18 1999-11-18 Novel compounds

Country Status (3)

Country Link
AU (1) AU1653101A (en)
SE (1) SE9904177D0 (en)
WO (1) WO2001035959A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1347971B1 (en) 2000-12-21 2006-03-01 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7169771B2 (en) 2003-02-06 2007-01-30 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
EP1781690B1 (en) * 2004-08-27 2011-06-29 ChronTech Pharma AB Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
WO2006028836A1 (en) * 2004-09-01 2006-03-16 Ethicon, Inc. Wound healing
WO2006109196A2 (en) * 2005-02-04 2006-10-19 Tripep Ab Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
JP6218229B2 (en) 2011-12-28 2017-10-25 京都府公立大学法人 Normalization of corneal endothelial cell culture
US10813920B2 (en) 2013-11-14 2020-10-27 The Doshisha Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8900564D0 (en) * 1989-02-17 1989-02-17 Astra Ab NOVEL MEDICINAL USE
SE9002659D0 (en) * 1990-08-15 1990-08-15 Astra Ab NEW PHARMACEUTICAL FORMULATIONS
SE9302333D0 (en) * 1993-07-06 1993-07-06 Ab Astra NEW COMPOUNDS
ZA944647B (en) * 1993-07-06 1995-01-06 Astra Ab Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
WO1999032111A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS

Also Published As

Publication number Publication date
WO2001035959A1 (en) 2001-05-25
AU1653101A (en) 2001-05-30

Similar Documents

Publication Publication Date Title
RU2395500C2 (en) 2,4-pyrimidine diamines used in treating neoplastic diseases, inflammatory and immune disorders
CY1111693T1 (en) ANTIQUE FACTORS
SE0104332D0 (en) Therapeutic agents
WO2003080580A3 (en) Quinoline derivatives and their use as 5-ht6 ligands
EA200200716A1 (en) ARYL CONDENSED AZOPOLYCYCLIC COMPOUNDS
ATE390421T1 (en) AMINOHETEROCYCLES AS VR-1 ANTAGONISTS FOR THE TREATMENT OF PAIN
MXPA04000532A (en) 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands.
EA200500018A1 (en) BENZONE-CONDENSED HETEROARILAMIDE TYENOPIRIDIN DERIVATIVES USED AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS, INCLUDING THEM, AND THEIR APPLICATION
RU92004336A (en) WATER-SOLUBLE DERIVATIVES OF CAMPTOTECINE, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING ENZYM TOOPOISOMERS, INTERMEDIATE PRODUCTS
YU96103A (en) New indole derivatives with 5-ht6 receptor affinity
RU2003120080A (en) ORTHO-SUBSTITUTED NITROGEN-CONTAINING BISARYL COMPOUNDS FOR APPLICATION AS POTASSIUM CHANNEL INHIBITORS, AND ALSO CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
EA200500377A1 (en) PYRAZOL DERIVATIVES AS INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF)
EA200701780A1 (en) ANTI-TUMOR MEDICINE
AP1564A (en) Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.
BG94282A (en) 2,9-DISUBSTITUTED-4H-PYRIDO/1,2,-A/PYRIMIDIN-4-ONES
SE9904177D0 (en) Novel compounds
DE602004015277D1 (en) SUBSTITUTED 1-PHTHALAZINEAMINS AS VR-1 ANTAGONISTS
DK160686A (en) TRI AND TETRACYCLIC COMPOUNDS
EA200400219A1 (en) QUINOLINE DERIVATIVES AND THEIR USE AS ANTI-TUMOR FACILITIES
DK0871626T3 (en) Triazolones as Apolipoprotein-B Synthesis Inhibitors
MX9405111A (en) NEW DERIVATIVES OF (1-PHENYL-1-HETEROCICLIL) METHANOL AND (1-PHENYL-1-HETEROCICLIL-METHYLAMINE).
CY1106576T1 (en) SUBSTITUTED 2-PYRROLIDIN-2-YL-1H-INDOLE DERIVATIVES FOR THE TREATMENT OF MIGRAINE
ES2099180T3 (en) DERIVATIVES OF BENZOPYRAN AND PROCEDURES FOR ITS PREPARATION.
ATE499373T1 (en) DIAZASPIROPIPERIDINE DERIVATIVES
EA200401077A1 (en) 2-oxazolamines and their use as antagonists of the 5-ht2b receptor